Other headlines:Miller joins fMRI companyYankees take Philips ‘out to the ballpark’
A new facility for making GE digital mammography detectors opened June 5 near the Global Research center that pioneered the flat panel. The sprawling plant, covering 230,000 square feet, cost $165 million to construct at the Rensselaer Technology Park in North Greenbush, NY. The new facility will fabricate the detectors now integrated into GE's Senographe digital mammography system, as well as ones for the company's next-generation breast tomosynthesis systems, which will acquire volumetric data about the breast. More than 95% of the flat-panel detectors manufactured by GE since 1999 are still in service, according to GE. About 4000 GE Senographe systems are currently in use worldwide. The first such system was shipped in 2000.
Former Vital Images chief executive Jay D. Miller has taken the reins as president and CEO of Kappametrics, a Chantilly, VA, company specializing in technology that records EEG data in real-time during fMR scans of the brain. Pending FDA marketing clearance, the company's flagship product, fEEG, promises a more detailed mapping of brain activity to improve the understanding and diagnosis of chronic neurological disorders. Kappametrics plans to pitch fEEG initially for academic and clinical research.
The New York Yankees have signed Philips Healthcare. An agreement that makes Philips the ball club's official supplier of medical equipment will bring digital radiography and external defibrillators to Yankee Stadium. The Philips BuckyDiagnost will be installed inside the Yankees' clubhouse. Automated external defibrillators will be available in player areas and in select locations throughout the stadium to provide emergency care to fans, if needed.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
Mammography-Based AI Abnormality Scoring May Improve Prediction of Invasive Upgrade of DCIS
April 9th 2024Emerging research suggests that an artificial intelligence (AI) score of 75 or greater for mammography abnormalities more than doubles the likelihood of invasive upgrade of ductal carcinoma in situ (DCIS) diagnosed with percutaneous biopsy.
Mammography Study: AI Improves Breast Cancer Detection and Reduces Reading Time with DBT
April 3rd 2024An emerging artificial intelligence (AI) model demonstrated more than 12 percent higher specificity and reduced image reading time by nearly six seconds in comparison to unassisted radiologist interpretation of digital breast tomosynthesis (DBT) images.